An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults

Halperin, Scott A.; Smith, Bruce R.; Russell, Margaret L.; Hasselback, Paul; Guasparini, Roland; Skowronski, Danuta M.; Meekison, William; Parker, Robert A.; Lavigne, Pierre; Barreto, Luis

doi:10.1016/s0264-410x(99)00415-6

Cited by 96 publications

(43 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The essential public health question that follows is whether the recently licensed adult-formulation acellular pertussis vaccine, which has been shown to be safe and immunogenic, should now be directed toward the control of pertussis in expanded age groups, particularly in preteens and teens [30].…”

Section: Discussionmentioning

confidence: 99%

The Changing Age and Seasonal Profile of Pertussis in Canada

et al. 2002

View full text Add to dashboard Cite

During the postvaccine era in Canada, most cases of pertussis have been reported in children <5 years of age, with the highest incidence, morbidity, and mortality in infants <1 year old. Population-based data, with very high laboratory confirmation rates and hospital separation and mortality statistics, chronicle the changing age and seasonal profile associated with pertussis over recent successive outbreaks in British Columbia, Canada. A large outbreak during 2000 highlights 2 important changes to the postvaccine profile. For the first time in Canada, the incidence of pertussis among preteens and teens surpassed that of all other age groups. At the same time, a decreasing incidence of pertussis among infants and preschool children highlights reduced susceptibility in the very young. Recent changes in the childhood immunization program (including introduction of an acellular pertussis vaccine), waning immunity, and changes in laboratory methods are considered in explaining these 2 simultaneous but divergent trends in the pertussis profile.

show abstract

Section: Discussionmentioning

confidence: 99%

The Changing Age and Seasonal Profile of Pertussis in Canada

et al. 2002

View full text Add to dashboard Cite

show abstract

“…These acellular vaccines were introduced into clinical practice in the United States in 1991 as the fourth and fifth doses of a five-dose series and were approved for use in the primary series in 1996 as part of the diphtheriatetanus-acellular pertussis combination vaccine. In addition to reducing the number of adverse events associated with pertussis vaccination, these formulations also proved to be at least as protective as their whole-cell predecessor (7,(12)(13)(14)(15)28). Recent studies have demonstrated that humans are capable of mounting an immune response to TcpF during V. cholerae infection, further validating the hypothesis that TcpF is a viable option for inclusion in a multisubunit cholera vaccine (16).…”

Section: Vol 73 2005mentioning

confidence: 84%

TcpF Is a Soluble Colonization Factor and Protective Antigen Secreted by El Tor and Classical O1 and O139 Vibrio cholerae Serogroups

Kirn

Taylor

2005

Infect Immun

View full text Add to dashboard Cite

Vibrio cholerae causes diarrhea by colonizing the human small bowel and intoxicating epithelial cells. Colonization is a required step in pathogenesis, and strains defective for colonization are significantly attenuated. The best-characterized V. cholerae colonization factor is the toxin-coregulated pilus (TCP). It has been demonstrated that TCP is required for V. cholerae colonization in both humans and mice. TCP enhances bacterial interactions that allow microcolony formation and thereby promotes survival in the intestine. We have recently discovered that the TCP biogenesis apparatus also serves as a secretion system, mediating the terminal step in the extracellular secretion pathway of TcpF. TcpF was identified in classical isolates of V. cholerae O1 as a soluble factor essential for colonization in the infant mouse cholera model. In the present study, we expanded our analysis of TcpF to include the O1 El Tor and O139 serogroups and investigated how TCP and TcpF act together to mediate colonization. Additionally, we demonstrated that antibodies generated against TcpF are protective against experimental V. cholerae infection in the infant mouse cholera model. This observation, coupled with the fact that TcpF is a potent mediator of colonization, suggests that TcpF should be considered as a component of a polyvalent cholera vaccine formulation.

show abstract

“…In a number of prelicensure studies, Tdap was tolerated well by adolescents and adults, with the nature and rate of adverse events associated with immunization not substantially different from those associated with the licensed and widely used Td vaccine. [14][15][16] However, these studies were completed in adolescents and adults who had received whole-cell pertussis vaccine for most or all of their previous doses of pertussis-containing vaccine. With the preschool booster, the lowest rates of injection-site reactions were reported by children who received a dose of acellular pertussis vaccine after 4 previous doses of whole-cell pertussis vaccine.…”

mentioning

confidence: 99%

“…Although HIV-specific IgG antibodies predominate over IgA in human milk, secretory IgA is found in the human milk of roughly 50% of infected women, has been shown to prevent epithelial HIV transcytosis, and is felt to be more mucosally active than IgG. 9 Mucosal HIV-specific IgA has been found in the genital tract of exposed uninfected individuals, implying a potential role in protective mucosal immunity, 14 although there are no data linking IgA to improved outcome in HIV-infected individuals. In effect, the authors hoped that the provision of maternal IgA in the milk of infected mothers might act as a form of passive infant immunization to protect against HIV acquisition.…”

mentioning

confidence: 99%

An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults

Cited by 96 publications

References 34 publications

The Changing Age and Seasonal Profile of Pertussis in Canada

The Changing Age and Seasonal Profile of Pertussis in Canada

TcpF Is a Soluble Colonization Factor and Protective Antigen Secreted by El Tor and Classical O1 and O139 Vibrio cholerae Serogroups

Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: Reassurance for the future

Contact Info

Product

Resources

About